Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine

Clinical Neuropharmacology

Volumn 24, Issue 4, 2001, Pages 232-234

  Miyata, Shinji ^a,b   Hamamura, Takashi ^b   Yoshinaga, Junji ^a   Nakamura, Yasushi ^a   Imamura, Takaki ^a   Hikiji, Akiyoshi ^a   Kuroda, Shigetoshi ^b  

^a HIROSHIMA CITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Frozen gait; L threo DOPS; Noradrenaline; Pure akinesia; Scrotonin; Tandospirone

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; SEROTONIN 1A AGONIST; TANDOSPIRONE; THREO 3,4 DIHYDROXYPHENYLSERINE;

AGED; AKINESIA; ARTICLE; CASE REPORT; FEMALE; GAIT DISORDER; GAZE PARALYSIS; HUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RECURRENT DISEASE; RIGIDITY; TREMOR;

AGED; ALDEHYDE-LYASES; BASAL GANGLIA DISEASES; DROXIDOPA; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; PIPERAZINES; PYRIMIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS;

EID: 0034904526     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200107000-00007     Document Type: Article

References (18)

1. L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism
2. Cases of pure akinesia without rigidity and tremor and with no effect by L-dopa therapy
3. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): Report of a case, with pharmacological considerations
4. Result of long-term administration of L-treo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy
5. Pure akinesia: An atypical manifestation of progressive supranuclear palsy
6. Akinesia - Concerning 2 cases of pure akinesia
7. The syndrome of "pure akinesia" and its relationship to progressive supranuclear palsy
8. Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms
9. Treatment of parkinsonism with 5-HT1A serotonin agonists
10. Buspirone in the treatment of tardive dyskinesia
11. Buspirone in levodopa-induced dyskinesias
12. Buspirone in the management of dyskinesias induced by L-dopa
13. Buspirone in Parkinson's disease
14. Pharmacological properties of SM-3997: A new anxioselective anxiolytic candidate
15. Effects of tandospirone in three behavioral tests for anxiolytics
16. Effect of tandospirone citrate in progressive supranuclear palsy
17. Serotonin 1A receptor agonists induced Fos protein expression in the locus coeruleus of the conscious rat
18. Biochemical evidence for the regulation of central noradrenergic activity by 5HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat